$OSTX News

OS Therapies Says New Bone Cancer Data Strengthens Case For Regulatory Filings

OS Therapies Announces Its Phase 2b Trial Of OST-HER2 In The Prevention Or Delay Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma Achieved Statistically Significant Benefit For OST-HER2 Treated Patients In Overall Survival At The 2.5-Year Mark

OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World

OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences

Lake Street Maintains Buy on OS Therapies, Lowers Price Target to $13

OS Therapies Reports First Quarter 2026 Financials and Provides Business Update

OS Therapies Q1 EPS $(0.27) Misses $(0.18) Estimate

OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026

OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor

Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX)

OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma

OS Therapies Says EMA's CAT Initiates Continuous Evaluation Of OST-HER2 CMA Request Regulatory Dossier For Prevention Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma

OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET

OS Therapies To Host Conference Call On April 30 To Review Data That Supported Recent PCT International Application For OST-HER2 Pharmacodynamic Biomarker1 As Surrogate Clinical Efficacy Endpoint

OS Therapies To Host Conference Call On April 30 To Review Data That Supported Recent PCT International Application For OST-HER2 Pharmacodynamic Biomarker1 As Surrogate Clinical Efficacy Endpoint

OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes

OS Therapies Files New Patent Application Covering Immune Signature In Response Therapeutic Candidates Developed Using Listeria Monocytogenes Platform

OS Therapies Appoints Craig Eagle, MD as Strategic Advisor

OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors

OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update